Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma
Status:
Terminated
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
In this trial the investigators want to combine chemotherapy with immunotherapy by giving the
patients Temozolomide, before vaccination. The investigators have also included hTERT and
survivin mRNA in the vaccine. Finally, the investigators want to introduce ex vivo T cell
expansion after lymphodepletion for the patients who show an immune response.